No Data
Wohua Pharmaceuticals: Report for the third quarter of 2024
Shandong Wohua Pharmaceutical: Half-year report for the year 2024.
Shandong Wohua Pharmaceutical: Summary of Half-Year Report in 2024.
Express News | Shandong Wohua Pharmaceutical: Net income in the first half of 2024 decreased by 70.21% year-on-year.
Shandong Wohua Pharmaceutical: 2024 Interim Performance Forecast
Shandong Wohua Pharmaceutical (002107.SZ): net income is expected to decrease by 64.52%-76.08% in the first half of the year.
On July 10th, Gelunhui reported that the net income attributed to shareholders of Shandong Wohua Pharmaceutical (002107.SZ) for the first half of 2024 is expected to be between 8.9 million yuan and 13.2 million yuan, a decrease ranging from 76.08% to 64.52% year-on-year. After deducting non-recurring gains and losses, the net income is expected to be between 8.2 million yuan and 12 million yuan, a decrease ranging from 77.02% to 66.38% year-on-year; the basic EPS is expected to be 0.0154 yuan/share to 0.0229 yuan/share. The company's core product, Wohua@Xin Keshu Tablet, will be released in 2023.
No Data
No Data